Lenalidomide Biocon

Lenalidomide, the active ingredient in Lenalidomide Biocon, is an immunomodulatory agent presented as a tablet for oral use. It treats certain blood cancers such as multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Biocon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is employed in hematologic malignancies that involve abnormal plasma or lymphoid cells.

- Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or newly diagnosed disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and delays disease progression. - Mantle Cell Lymphoma: contributes to tumor control when combined with other agents in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness often accompanied by vomiting. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Thromboembolic events: blood clots in veins or arteries. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Hepatotoxicity: liver enzyme elevations or liver injury.

Before initiating therapy, several safety considerations should be reviewed.

- Pregnancy: contraindicated; teratogenic risk requires effective contraception. - Thrombosis risk: assess and consider prophylactic anticoagulation in high‑risk patients. - Renal impairment: dose adjustment may be needed; monitor kidney function. - Hematologic monitoring: regular CBC to detect neutropenia or thrombocytopenia. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increased risk of bleeding when combined with lenalidomide‑induced thrombocytopenia. - Immunosuppressants (e.g., cyclosporine): may enhance immunomodulatory effects and toxicity.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - NSAIDs: additive risk of gastrointestinal bleeding. - Vaccines: live vaccines should be avoided due to altered immune response.